Aries: (April 19–March 20) It goes without saying that you are fully aware of the thrilling and fast-paced cycle of change you are in. The issue? Some others are uncomfortable, if not terrified, while

Researchers recently stated that a big U.S. study did not find any evidence linking the use of Ozempic or Wegovy to an increase in suicidal ideation.Semaglutide is the same active component found in both the obesity medication Wegovy and the type 2 diabetes medication Ozempic.Over 1.8 million patients' electronic medical records were included in the analysis. In fact, when compared to individuals using other drugs for diabetes or weight reduction, researchers discovered that semaglutide users had a decreased incidence of both new and recurrent suicidal ideation.Semaglutide is a member of the GLP-1 agonist medication class, which was created to treat type 2 diabetes. The medications not only assist lower blood sugar levels but also make you feel full.The European Medicines Agency launched an investigation as a result of worries over reports of suicidal thoughts associated with semaglutide. Suicidal ideation has been identified by the U.S. Food and Drug Administration (FDA) as a potential safety risk associated with GLP-1 medications.According to a Reuters investigation last year, the FDA has been notified of 265 cases of suicide behavior or thoughts in patients who were on semaglutide or related medications since 2010. Thirty-six of those reports detail an apparent suicide or suicide death.Such incidents do not demonstrate a link between a medication and a negative effect. However, they can alert authorities to the need to investigate a particular risk.The work was published in the journal Nature online. The U.S. National Institutes of Health provided funding for it. The researchers looked at data on roughly 1.6 million individuals with type 2 diabetes who were prescribed Ozempic or other medicines, and 240,258 people in the United States who were prescribed Wegovy or other medications for weight loss.Nearly 53,000 Wegovy patients were compared by researchers to an equal number of closely matched users of other weight-loss medications. They discovered that 0.11 percent of Wegovy users reported experiencing suicide thoughts for the first time within the first six months of use. In contrast, 0.43 percent of users of medications other than those in the same class as semaglutide do the same.

Wegovy was associated with a 73 percent lower incidence of first-time suicide ideation after accounting for other risk factors, according to the study. Compared to 14 users of the other medicines, none of the patients in the Wegovy group reported having attempted suicide, according to the findings.Compared to other weight-loss medications, Wegovy lowered the incidence of recurrent suicidal thoughts in individuals who had previously experienced them by 56%. Comparing Ozempic's usage to that of other diabetes medications, similar trends were seen.The researchers discovered that the results held true for both semaglutide types regardless of the patients' sex, age, or ethnicity. A study of this kind cannot demonstrate that GLP-1 agonists do not raise the possibility of suicide thoughts. But the results might allay worries. The statistical significance of variations in the number of actual suicide attempts could not be determined by the researchers. Suicidal ideations and suicide attempts are "critically different," according to the experts. Professor Pamela Davis teaches at Ohio's Case Western Reserve School of Medicine. She contributed to the study's writing. She stated that it is crucial "to understand all its potential complications" given Ozempic's rising popularity.Suggestions that the medicine may promote suicidal thoughts are not substantiated by “this very large and diverse population in the U.S.,” Davis added.